Biotech Roquefort To Buy Cancer Drug License For £32M
Biotechnology company Roquefort confirmed Monday that it has conditionally acquired the license for a "highly promising" experimental cancer treatment drug for an initial consideration of about £31.9 million ($43 million)....To view the full article, register now.
Already a subscriber? Click here to view full article